INDEPENDENT NEWS

Product For Antibiotic Associated Side-Effects

Published: Tue 18 Feb 2003 11:27 AM
Blis Technologies Launches Product For Antibiotic Associated Side-Effects
New Zealand biotechnology company BLIS Technologies has released a world first new product that restores the good and naturally occurring beneficial bacteria in the mouth, throat and intestinal tract following a course of antibiotics.
BLIS Bio RESTORE has been developed in response to growing demand from pharmacists wanting a well researched intestinal health product that complements the oral beneficial bacteria in BLIS K12 Throat Guard, which BLIS Technologies launched in New Zealand last June and is preparing to market internationally.
BLIS Technologies chief executive Kelvin Moffatt said BLIS Bio RESTORE had a key competitive advantage over other products in the marketplace in that it is the only product containing both beneficial oral and intestinal bacteria, and is also underpinned by substantial strain specific research by credible and mainstream scientists.
“BLIS Bio RESTORE and BLIS K12 Throat Guard, are based on well researched beneficial strains of bacteria and offer the opportunity for profound changes in the way the health of people is managed, now and in the future.”
“The British Medical Journal recently published the results of a meta analysis on the benefits of using supplementary intestinal beneficial bacteria following antibiotic use, and this has raised further interest within the healthcare profession.”
According to Pharmac figures, there are 2.9 million antibiotic prescriptions written in New Zealand each year and antibiotic usage is similar to comparable western countries. This provides an indication of the size of the potential market for BLIS Bio RESTORE.
It is estimated that up to a quarter of people taking a course of antibiotics may suffer associated side-effects and by reducing these, patients are more likely to complete their course of antibiotic treatment.
“Antibiotics are an effective and appropriate treatment for many bacterial infections, however antibiotics can eliminate not only the undesirable bacteria, but also the naturally occurring protective bacteria.
…. / 2
2
“A decrease in the numbers of supportive bacteria can lead to the side-effects associated with antibiotic use.”
BLIS Bio RESTORE is a high dose, three day course containing both the K12 beneficial oral bacteria and specially selected strains of beneficial intestinal bacteria including the HOWARU™ RHAMNOSUS and HOWARU™ BIFIDO strains licensed from Copenhagen based firm DANISCO.
The new HOWARU™ strains are amongst the most thoroughly researched intestinal strains worldwide, both in terms of safety and in delivering health benefits, with much of that research having been carried out in New Zealand.
Classified as a Dietary Supplement, BLIS Bio RESTORE will be distributed through pharmacies only, however it will also be supported by a General Practitioners’ programme.
BLIS Bio RESTORE can be used by adults and children over the age of three.
The lozenges in BLIS Bio RESTORE contain the naturally occurring oral bacteria Streptococcus salivarius K12 while three specially selected cultures of lactic acid forming intestinal bacteria are contained in the sachets taken by dissolving the contents in water, milk or fruit juice. This combination provides the first complete solution for restoring both oral and intestinal health following a course of antibiotics.”
BLIS Bio RESTORE will be packaged in one convenient pack containing the three specially selected intestinal strains in sachets and K12 Throat Guard lozenges and is expected to retail at approximately $19.95.
Mr Moffatt said BLIS Technologies will continue to bring new products to the market, the next one, a protective bacteria for tooth decay, is likely to be on the market within 12 months with clinical trials about to begin in association with the University of Otago Dental School. Others include prevention and treatment of ear infections, acne and skin infections, bovine mastitis, similarly using beneficial bacteria to help eliminate potentially undesirable bacteria.

Next in Business, Science, and Tech

General Practices Begin Issuing Clause 14 Notices In Relation To The NZNO Primary Practice Pay Equity Claim
By: Genpro
Global Screen Industry Unites For Streaming Platform Regulation And Intellectual Property Protections
By: SPADA
View as: DESKTOP | MOBILE © Scoop Media